Hoffmann P, Dvorák P, Morávek P, Safránek H
Radiologická klinika LF UK a Fakultní nemocnice v Hradci Králové.
Rozhl Chir. 2007 Sep;86(9):494-9.
AIM OF THE ARTICLE: To evaluate first clinical and interventional radiological features and experience with computed tomography-guided percutaneous radiofrequency ablation of the renal tumors using StarBurst instruments (RITA Medical System, Inc., Mountain View, CA).
The group of 8 patients with mean age 77.75 +/- 4.38 years underwent during a period of 12 months CT-guided RFA treatments for enhancing renal masses, with a mean size 21.78 +/- 9.81 mm, using only conscious sedation and local anaesthesia. All patients had multiple medical comorbidities that limited or completely contraindicated surgical treatment. In two cases tumors involved solitary kidney. Patients were hospitalized in urologic department of University hospital, where possible early complications were monitored. Patients were followed with clinical status and renal function studies. Also enhanced imaging (enhanced computed tomography or magnetic resonance in one case) were performed 1 month, 3, 6 and 12 months after initial procedure. Successful ablation was defined as a lack of enhancement of the renal mass eventually with a scar-like retraction of surrounding renal parenchyma.
During a 12-months period (from February 2006 to February 2007) 10 percutaneous CT-guided RFA treatments in 8 patients were performed. In 6 patients (75%) were single treatment successful, 1 had an initial failure and underwent reablation successfully and 1 underwent second treatment for coexisting small tumor in the same kidney. All patients stayed in hospital for a 3 days, none from this group died during this period and none need not to be excluded from this study. We did not reveal any early complication. Average length of the following-up was 5.75 months.
CT-guided percutaneous radiofrequency ablation is a promising therapeutic alternative of surgical methods (nephrectomies or nephron-sparing surgical devices) especially with small renal tumors in patients with multiple medical comorbidities, tumors in solitary kidneys and in rarer indications. The procedure were well tolerated using only conscious sedation and local anaesthesia. None early complication was observed. Other useful informations will be probably captured by following-up this group and by monitoring new patients.
本文目的:评估使用StarBurst仪器(RITA医疗系统公司,加利福尼亚州山景城)对肾肿瘤进行计算机断层扫描引导下经皮射频消融的首次临床和介入放射学特征及经验。
8例平均年龄77.75±4.38岁的患者在12个月期间接受了CT引导下的RFA治疗,用于治疗增强性肾肿块,平均大小为21.78±9.81毫米,仅使用清醒镇静和局部麻醉。所有患者都有多种内科合并症,这些合并症限制或完全禁忌手术治疗。2例患者的肿瘤累及孤立肾。患者在大学医院泌尿外科住院,监测可能出现的早期并发症。对患者进行临床状况和肾功能研究随访。在初次手术后1个月、3个月、6个月和12个月还进行了增强成像(1例为增强计算机断层扫描或磁共振成像)。成功消融定义为肾肿块最终无强化,并伴有周围肾实质瘢痕样回缩。
在12个月期间(从2006年2月至2007年2月),对8例患者进行了10次经皮CT引导下的RFA治疗。6例患者(75%)单次治疗成功,1例初次治疗失败后再次消融成功,1例因同一肾脏并存小肿瘤接受了二次治疗。所有患者住院3天,该组在此期间无死亡病例,且无需排除在本研究之外。未发现任何早期并发症。平均随访时间为5.75个月。
CT引导下经皮射频消融是手术方法(肾切除术或保留肾单位的手术器械)的一种有前景的治疗替代方法,尤其适用于有多种内科合并症的小肾肿瘤患者、孤立肾肿瘤患者以及罕见适应症患者。仅使用清醒镇静和局部麻醉,该手术耐受性良好。未观察到早期并发症。通过对该组患者的随访和对新患者的监测,可能会获得其他有用信息。